Literature DB >> 16963160

The antimicrobial peptide cathelicidin interacts with airway mucus.

Kerstin Felgentreff1, Christoph Beisswenger, Matthias Griese, Tanja Gulder, Gerhard Bringmann, Robert Bals.   

Abstract

Antimicrobial peptides (AMPs) and mucins are components of airway secretions and both contribute to the innate host defense system. At neutral pH, AMPs are positively charged, mucins negatively. It was the aim of the study to test whether these opposite charges result in interactions between AMPs and mucins. We measured binding of mucins isolated from porcine gastric mucosa to the cathelicidin LL-37 coated to multiwell plates and found that LL-37 electrostatically interacts with mucins. Circular dichroism spectra of the peptide revealed the induction of alpha-helical conformation by mucins. Addition of mucins to solutions of LL-37 significantly decreased the antimicrobial activity of the peptide against Pseudomonas aeruginosa and Streptococcus pneumoniae. We then tested whether LL-37 is bound to mucins in airway secretions from human subjects and found that a significant proportion of the peptide and its propeptide are bound to high molecular weight components. Together these data show that cationic AMPs interact with anionic mucins in airway secretions. Functions of AMPs are modulated by this interaction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16963160     DOI: 10.1016/j.peptides.2006.07.018

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  30 in total

1.  Differential In Vitro and In Vivo Toxicities of Antimicrobial Peptide Prodrugs for Potential Use in Cystic Fibrosis.

Authors:  Éanna Forde; André Schütte; Emer Reeves; Catherine Greene; Hilary Humphreys; Marcus Mall; Deirdre Fitzgerald-Hughes; Marc Devocelle
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 2.  Host defense peptides in the oral cavity and the lung: similarities and differences.

Authors:  G Diamond; N Beckloff; L K Ryan
Journal:  J Dent Res       Date:  2008-10       Impact factor: 6.116

Review 3.  Effects of airway surface liquid pH on host defense in cystic fibrosis.

Authors:  Abigail R Berkebile; Paul B McCray
Journal:  Int J Biochem Cell Biol       Date:  2014-02-19       Impact factor: 5.085

Review 4.  Supramolecular dynamics of mucus.

Authors:  Pedro Verdugo
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

Review 5.  Vitamin D and Otitis Media.

Authors:  Rebecca E Walker; Jim Bartley; Carlos A Camargo; Edwin A Mitchell
Journal:  Curr Allergy Asthma Rep       Date:  2019-06-03       Impact factor: 4.806

6.  Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13.

Authors:  Robert Bucki; Dorota B Namiot; Zbigniew Namiot; Paul B Savage; Paul A Janmey
Journal:  J Antimicrob Chemother       Date:  2008-05-01       Impact factor: 5.790

7.  Functionalized positive nanoparticles reduce mucin swelling and dispersion.

Authors:  Eric Y T Chen; Yung-Chen Wang; Chi-Shuo Chen; Wei-Chun Chin
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

Review 8.  Intestinal barrier in inflammatory bowel disease.

Authors:  Lena Antoni; Sabine Nuding; Jan Wehkamp; Eduard F Stange
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

9.  Interleukin 13 exposure enhances vitamin D-mediated expression of the human cathelicidin antimicrobial peptide 18/LL-37 in bronchial epithelial cells.

Authors:  J A Schrumpf; M A J A van Sterkenburg; R M Verhoosel; S Zuyderduyn; P S Hiemstra
Journal:  Infect Immun       Date:  2012-10-08       Impact factor: 3.441

10.  Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice.

Authors:  Katarzyna Leszczyńska; Andrzej Namiot; David E Fein; Qi Wen; Zbigniew Namiot; Paul B Savage; Scott Diamond; Paul A Janmey; Robert Bucki
Journal:  BMC Microbiol       Date:  2009-09-03       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.